Trial Profile

An open label study of high concentration inhaled nitric oxide (NO) using the LungFit system for COVID-19 patients in Israel

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 31 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nitric oxide (Primary)
Indications COVID-19 pneumonia; Pneumonia
Focus Therapeutic Use
Sponsors Beyond Air

Most Recent Events

24 Oct 2022 According to a Beyond Air company media release, results from this trial were presented at the at IDWeek 2022.
24 Oct 2022 Positive results published in the Beyond Air Media Release.
18 Apr 2022 According to a Beyond Air company media release, data from this trial will be presented at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2022) (Abstract : 00400).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com